Art

J-GLOBAL ID：201602239732956759   Reference number：16A0814915

Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance

乾癬性関節炎,膿疱性乾癬または乾癬性紅皮症あり,またはなしの尋常性乾癬の日本人患者におけるインフリキシマブ治療の安全性プロファイルと効果:前向き市販後調査からの結果

Author (6)： Torii Hideshi (Division of Dermatology, Tokyo Yamate Medical Center, Tokyo, Japan) ,  Terui Tadashi (Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan) ,  Matsukawa Miyuki (Pharmacovigilance and Quality Assurance Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) ,  Takesaki Kazumi (Pharmacovigilance and Quality Assurance Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) ,  Ohtsuki Mamitaro (Department of Dermatology, Jichi Medical University, Shimotsuke, Japan) ,  Nakagawa Hidemi (Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan)
Material： Journal of Dermatology  (J Dermatol)
Volume： 43  Issue： 7  Page： 767-778  Publication year： Jul. 2016 
JST Material Number： W1578A  ISSN： 0385-2407  Document type： Article
Article type： 原著論文  Country of issue： Australia (AUS)  Language： ENGLISH (EN)

Thesaurus term： *psoriasis ,...
Semi thesaurus term： Psoriasis pustular ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0814915&from=J-GLOBAL&jstjournalNo=W1578A") }}

Author keywords (5)： infliximab ,  Japanese ,  post-marketing surveillance ,  psoriasis ,  safety and efficacy

JST classification (2)： Drug therapy(=pharmacotherapy)for skin diseases  (GF05020A) ,  Clinical application of drugs acting on integumentum commune  (GW12020J)

Reference (37)：

• Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-1204.
• Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-1912.
• Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010; 24(Suppl 1): 3-14.
• Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009; 3: 183-191.
• Grainger R, Harrison AA. Infliximab in the treatment of ankylosing spondylitis. Biologics 2007; 1: 163-171.

Terms in the title (11)： 乾癬性関節炎 ,  膿疱性乾癬 ,  乾癬性紅皮症 ,  尋常性乾癬 ,  日本人 ,  患者 ,  インフリキシマブ ,  治療 ,  安全性 ,  プロファイル ,  市販後調査